Clinical Trial Update: Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer [NA]

View source ↗

Summary

This terminated trial evaluated Cu-64 TP3805 as a PET imaging agent in breast cancer, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cu-64 TP3805 (Copper-64 TP3805)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Breast Carcinoma | NA | Status: TERMINATED | Results posted: 2018-01-09